Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC+

For NF1-GISTs <30 mm, prognosis without relapse is excellent. RECKGIST score accurately predicts recurrence and needs to be validated in an external cohort, but it may help treatment decision making. No efficacy of adjuvant treatment was observed.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2025-03-01
DOI
https://doi.org/10.1016/j.esmoop.2025.104477
Citations
3
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
4.17
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC+

F. Bertucci, Lucie Monceau-Baroux, L. Chaigneau, Marie Müller et al.
3 citations
ESMO Open
Neurofibromatosis and Schwannoma Cases
4.17
article

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC+

F. Bertucci, Lucie Monceau-Baroux, L. Chaigneau, Marie Müller, Iradj Sobhani, Marc Pracht, François Poumeaud, P. Wolkenstein, Sylvain Manfrédi, H. Dupuis, Farouk Mourthadhoi, Sarah Watson, David Tougeron, Jean‐Yves Blay, François Ghiringhelli, Marie Vinches, Vincent Hautefeuille, Nicolas Penel, Laura Calavas, Adrien Grancher, Olivier Bouché, Mehdi Brahmi, W. Lahlou, Morgane Helyon, Jean‐Emmanuel Kurtz, Thierry Lecomte, Maud Toulmonde, Damien Bruyat, Nicolas Régenet, Claude Cuvelier, Guillaume Roquin, B. Verret
article en
3 citations

Abstract

For NF1-GISTs <30 mm, prognosis without relapse is excellent. RECKGIST score accurately predicts recurrence and needs to be validated in an external cohort, but it may help treatment decision making. No efficacy of adjuvant treatment was observed.

ESMO OpenVol. 10(3)
Université de Tours (FR), Inserm (FR), Université de Bourgogne (FR), Université Paris Cité (FR), Aix-Marseille Université (FR), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Universitaire Henri-Mondor (FR), Université de Poitiers (FR), Centre Hospitalier Universitaire de Besançon (FR), Institut de Cancérologie Strasbourg (FR), Centre Georges François Leclerc (FR), Centre Hospitalier Universitaire de Tours (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Hôpital Européen Georges-Pompidou (FR), University of Clermont Auvergne (FR), Centre Léon Bérard (FR), Centre Hospitalier Universitaire de Reims (FR), Centre Eugène Marquis (FR), Institute Cancer De La Loire Lucien Neuwirth (FR), Institut Claudius Regaud (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Hôpitaux Universitaires Henri-Mondor (FR), Centre Oscar Lambret (FR), Centre Hospitalier Régional Universitaire de Brest (FR), Institut Bergonié (FR), Institut de Recherche en Cancérologie de Montpellier (FR), Institut Paoli-Calmettes (FR), Hôpital Claude Huriez (FR), Université d'Angers (FR), Université de Rouen Normandie (FR), Institut Curie (FR), Université de Reims Champagne-Ardenne (FR), Nantes Université (FR)
Openalex Percentile: Top 7%
Neurofibromatosis and Schwannoma Cases
4.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.